A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Completed · Phase 3 · NCT05109234
Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
At a glance
- Research payments reported, 2025
- $126,904
- U.S. investigators named
- 6
- Sites paid
- 7
- Planned or actual enrollment
- 84
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Brivaracetam Film-coated tablet (drug), Brivaracetam oral solution (drug)
- Dates
- Started 2022-03-30; completion 2025-03-18
- Results posted
- Yes
The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
From ClinicalTrials.gov, last updated 2025-10-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $126,904 in research payments for this study in 2025 (7 payments).
Products named: Briviact
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Pongkiat Kankirawatana, M.D. Child Neurology · Birmingham, AL
- Donald J. Phillips, M.D. Neurology · Orange, CA
- Andrew White, MD Neurology · Denver, CO
- Yong D. Park, MD Child Neurology · Augusta, GA
- Gautam S. Popli, M.D. Child Neurology · Winston Salem, NC
- Carlos Lastra, M.D. Child Neurology · New Brunswick, NJ
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Alabama Hospital, AL $85,429
- Wake Forest University Health Sciences $12,668
- Children's Hospital of Orange County, CA $9,347
- Augusta University Research Inst. Inc. $7,445
- Saint Peter's University Hospital, NJ $5,626
- Ghsu Research Institute, Inc. $4,389
- Denver Health & Hospital Authority, CO $2,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.